Fixed dosing of liposomal amphotericin b in morbidly obese individuals

Roeland E. Wasmann, Cornelis Smit, Eric P.H. van Dongen, René M.J. Wiezer, Jill Adler-Moore, Yvo M. de Beer, David M. Burger, Catherijne A.J. Knibbe, Roger J.M. Brüggemann

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

Original languageEnglish
Pages (from-to)2213-2215
Number of pages3
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume70
Issue number10
DOIs
Publication statusPublished - 6 May 2020
Externally publishedYes

Keywords

  • Fungal infection
  • Fungal treatment
  • Obese
  • Optimal dosing
  • Population pharmacokinetics

Fingerprint

Dive into the research topics of 'Fixed dosing of liposomal amphotericin b in morbidly obese individuals'. Together they form a unique fingerprint.

Cite this